Judo Bio
Cambridge, US · Founded 2021 · 34 employees on LinkedIn · 5 known investors
Find your way into Judo Bio
929 people in our graph share verified history with the Judo Bio team — schools, employers, funds. One of them is your warm intro.
Nicole Gaudelliunlockedknows Andrew Fraley · together at Boston College (overlapped)
×2knows the team · via PwC
knows the team · via Ensemble Therapeutics Corporation
×2knows the team · via DePauw University
×3knows the team · via Boston College
knows the team · via Korro Bio
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform. The company applies RNA-based therapeutics that harness a natural endogenous mechanism for receptor-mediated uptake by specific kidney cell types to silence disease-modifying genes.
Founders & leadership
Judo Bio was founded in 2021 by Andrew Fraley and Alfica Sehgal.
AF
Andrew FraleyinCo-founderCo-founder and Chief Technology Officer of Judo Bio, Andrew Fraley previously co-founded Korro Bio, a company developing RNA editing therapeutics, and has held leadership roles advising biotech startups in genetic medicine and RNA therapeutics.
AS
Alfica SehgalinFounder
OC
JJ
JAMES JEFFREY GOATERExecutive
SR
Simon ReadinCEOSimon Read is Executive Chairman of Judo Bio, which develops oligonucleotide medicines for systemic and renal diseases using its STRIKE platform. He previously founded and served as CEO of Mariana Oncology (acquired by Novartis in 2024) and held the Chief Scientific Officer role at Ra Pharma (acquired by UCB Pharma in 2020), bringing over 25 years of R&D experience in drug development across GlaxoSmithKline, AstraZeneca, and Roche/Genentech.
WH
William Ho
CP
Board
KB
GG
AM
ANKIT MAHADEVIABoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$55M disclosed across 3 rounds · 2022–2024
▶$25MraisedAug 2024 · 21 investors · BiotechnologyRule 506(b)
▶$25MraisedAug 2024 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- GEORGE GOLUMBESKIDirector
- OMMER CHOHANExecutive Officer
- ANKIT MAHADEVIADirector
- JAMES JEFFREY GOATERExecutive Officer, Director
- KEVIN BITTERMANExecutive Officer, Director
- SAM BJORKDirector
- Amount sold
- $25M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$5MraisedJun 2024 · 2 investors · BiotechnologyRule 506(b)
▶$5MraisedJun 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- OMMER CHOHANExecutive Officer
- CHELSEA PLACE JOHNSONDirector
- KEVIN BITTERMANExecutive Officer, Director
- JAMES JEFFREY GOATERExecutive Officer, Director
- ANKIT MAHADEVIADirector
- HUI TIANDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$25MraisedNov 2023 · 2 investors · BiotechnologyRule 506(b)
▶$25MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAMES JEFFREY GOATERDirector
- CHELSEA PLACE JOHNSONDirector
- ANKIT MAHADEVIADirector
- KEVIN BITTERMANExecutive Officer, Director
- HUI TIANDirector
- OMMER CHOHANExecutive Officer
- Amount sold
- $25M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Judo Bio went on to found or lead other companies.
Competitors · 2
by search overlapSudo Bio7 shared keywordsSudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions. The company focuses on drug development and translational biology to address unmet medical needs.
Ditto Biosciences6 shared keywordsDitto Bio uses AI to identify protein candidates from parasites and pathogens for treating autoimmune diseases. The company mines natural compounds from viruses, ticks, and worms whose immune-modulating properties have evolved over millions of years.
Companies competing with Judo Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Judo Bio do?
- Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform. The company applies RNA-based therapeutics that harness a natural endogenous mechanism for receptor-mediated uptake by specific kidney cell types to silence disease-modifying genes.
- Who founded Judo Bio?
- Judo Bio was founded by Andrew Fraley, Alfica Sehgal in 2021.
- Who are Judo Bio's investors?
- Judo Bio's investors include Atlas Venture, Digitalis Ventures, The Column Group, Droia Ventures, YK Bioventures.
- How much funding has Judo Bio raised?
- Judo Bio has disclosed $55M raised across 3 rounds.
- Where is Judo Bio headquartered?
- Judo Bio is headquartered in Cambridge, US.